Aarey Drugs & Pharmaceuticals Ratios

Aarey Drugs & Pharmaceuticals Ltd Ratios

The Aarey Drugs & Pharmaceuticals Ltd Ratios page provides a complete fundamental analysis of Aarey Drugs & Pharmaceuticals Ltd using key valuation, profitability, and financial strength metrics. Investors tracking Aarey Drugs & Pharmaceuticals Ltd Ratios closely monitor D/E, EV, EV/EBITDA, P/B, P/CF, P/E, P/S, and ROE% to evaluate the company's financial performance and valuation trends over time.

Aarey Drugs & Pharmaceuticals Ltd (NSE: AAREYDRUGS, BSE: 524412) is currently trading at ₹69.28, with a market capitalization of ₹1.95B. As a major player in the Health technology sector and Pharmaceuticals: major industry, Aarey Drugs & Pharmaceuticals Ltd remains a key stock for fundamental analysis using Aarey Drugs & Pharmaceuticals Ltd Ratios.

Aarey Drugs & Pharmaceuticals Ltd Ratios: Valuation Overview

Price to Earnings Ratio (P/E)

The Aarey Drugs & Pharmaceuticals Ltd P/E ratio currently stands at 23.67, making it one of the most tracked metrics in Aarey Drugs & Pharmaceuticals Ltd Ratios.

Historically, the Aarey Drugs & Pharmaceuticals Ltd P/E ratio has shown strong fluctuations:

• 2024: 23.67
• 2023: 24.24
• 2022: 15.93
• 2021: 15.21
• 2020: 8.33

The decline in Aarey Drugs & Pharmaceuticals Ltd P/E ratio suggests improving earnings relative to stock price.

Price to Book Ratio (P/B)

The Aarey Drugs & Pharmaceuticals Ltd P/B ratio reflects how the market values the company's net assets. Current P/B ratio is 0.69.

Historical P/B trend:

• 2024: 0.69
• 2023: 0.94
• 2022: 0.51
• 2021: 0.85

Aarey Drugs & Pharmaceuticals Ltd shows reasonable valuation compared to its asset base.

Price to Sales Ratio (P/S)

The Aarey Drugs & Pharmaceuticals Ltd P/S ratio currently stands at 0.20, an important part of Aarey Drugs & Pharmaceuticals Ltd Ratios for revenue valuation.

Historical P/S ratio:

• 2024: 0.20
• 2023: 0.29
• 2022: 0.14
• 2021: 0.20

A stable or declining Aarey Drugs & Pharmaceuticals Ltd P/S ratio indicates cautious market sentiment.

Aarey Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio (P/CF)

The Aarey Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio is a key valuation metric that shows how much investors pay for each unit of cash flow. Current P/CF ratio is 106.48.

Historical Aarey Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio:

• 2024: 106.48
• 2023: 0
• 2022: 0
• 2021: 42.35
• 2020: 18.73

The rising Aarey Drugs & Pharmaceuticals Ltd Price to Cash Flow Ratio indicates premium valuation based on cash flow.

Aarey Drugs & Pharmaceuticals Ltd Enterprise Value Ratios

Enterprise Value (EV)

The Aarey Drugs & Pharmaceuticals Ltd EV currently stands at ₹1.27B, representing the total company valuation including debt.

Historical EV trend:

• 2024: 1.27B
• 2023: 1.42B
• 2022: 966.81M
• 2021: 1.14B

Aarey Drugs & Pharmaceuticals Ltd enterprise value consolidation suggests stable valuation.

EV/EBITDA Ratio

The Aarey Drugs & Pharmaceuticals Ltd EV/EBITDA ratio is currently 14.96, a key metric in Aarey Drugs & Pharmaceuticals Ltd Ratios to assess valuation relative to earnings.

Historical EV/EBITDA:

• 2024: 14.96
• 2023: 14.92
• 2022: 8.77
• 2021: 8.26

Higher Aarey Drugs & Pharmaceuticals Ltd EV/EBITDA suggests premium valuation.

Aarey Drugs & Pharmaceuticals Ltd Financial Strength Ratios

Debt to Equity Ratio (D/E)

The Aarey Drugs & Pharmaceuticals Ltd D/E ratio is currently 0.25, reflecting leverage and financial stability.

Historical D/E:

• 2024: 0.25
• 2023: 0.24
• 2022: 0.32
• 2021: 0.12

Aarey Drugs & Pharmaceuticals Ltd maintains a strong balance sheet with low debt levels.

Return on Equity (ROE %)

The Aarey Drugs & Pharmaceuticals Ltd ROE currently stands at 2.97%, showing profitability and capital efficiency.

Historical ROE:

• 2024: 2.97
• 2023: 3.74
• 2022: 3.26
• 2021: 6.17

Declining ROE indicates pressure on profitability.

Aarey Drugs & Pharmaceuticals Ltd Ratios Analysis Summary

The Aarey Drugs & Pharmaceuticals Ltd Ratios page provides a comprehensive view of the company's valuation and financial performance. Key metrics such as P/E, P/B, P/S, P/CF, EV, EV/EBITDA, D/E, and ROE help investors understand whether Aarey Drugs & Pharmaceuticals Ltd stock is undervalued, fairly valued, or overvalued.

Tracking Aarey Drugs & Pharmaceuticals Ltd Ratios regularly helps investors make informed decisions based on valuation trends, financial stability, and long-term growth potential.